The Digi‑Tech Pharma & AI Conference 2026, held on May 27–28, 2026, in London, brought together pharmaceutical companies, technology providers, regulators, and healthcare stakeholders to examine the role of digital technologies in the pharmaceutical industry. The conference focused on integrating AI, machine learning, data science, and digital health systems into drug discovery, clinical development, and patient care processes.
Pharma companies signaled a clear shift from experimentation to operationalization, positioning digital capabilities as core to the industry’s operating model. The focus extended beyond adoption to accelerating development timelines, improving decision-making, and aligning regulation with emerging technologies.
One of the strongest themes from the event was the practical use of Gen AI in drug discovery and early-stage research. The discussions showed how these technologies are being applied across target identification, where AI models analyze biological and genomic data to identify potential intervention points, and lead compound design, where algorithms optimize molecular structures based on predicted efficacy and safety profiles. Predictive modeling also emerged as an important tool for enabling earlier, better-informed decisions throughout the drug development process. Growing reliance on AI-driven approaches also reflects broader industry pressures. As highlighted in Avasant Life Sciences Digital Services 2026 Market Insights, the need to shorten time-to-market and mitigate the effects of the patent cliff is prompting a shift toward more efficient, data-driven R&D models. This growing adoption was also reflected at the regulatory level, with the US FDA receiving over 500[i] drug submissions containing AI components between 2016 and 2023, indicating the increasing integration of AI across the pharmaceutical life cycle.
Speakers highlighted the increasing reliance on AI-led discovery to connect diverse data sources. Algorithms and AI-based models process large-scale datasets to enable automated analysis, while multiomics integration combines genomic, proteomic, and other biological data with advanced analytics to generate deeper insight into disease mechanisms and therapeutic pathways. They also noted that data science approaches to drug combination discovery allow computational models to evaluate interactions and identify combinations with stronger therapeutic potential. Data.
The broader signal was a shift toward data-integrated, computationally enabled R&D models, in which digital tools and analytical platforms are becoming part of core scientific processes. Structured data, algorithmic analysis, and scalable computing infrastructure are increasingly important for supporting the design, testing, and advancement of pharmaceutical research.
Clinical development discussions reinforced how real-world data (RWD), real-world evidence (RWE), and digitally enabled trial models are becoming part of mainstream research and regulatory thinking. These data sources are not replacing traditional clinical trials; instead, they are complementing them with insights from routine clinical practice, patient outcomes, and longitudinal healthcare data. The scale of this transition was reflected in regulatory initiatives such as the European Medicines Agency’s DARWIN EU network, which, as of 2026, provided access to data from approximately 250[ii] million patients, had delivered over 110 studies since 2022, and operated with around 40 data partners.
Key areas of focus included:
Taken together, these areas point to a broader expansion of clinical development beyond conventional trial settings. Real-world insights, digital methodologies, and hybrid models are becoming more important to development strategies, regulatory evaluation, and life cycle management processes.
Another clear theme of the event was that the industry’s ability to act on data is becoming as important as its ability to generate it. Discussions on data science, big data, and informatics highlighted how AI tools are used for clinical data interpretation and how healthcare analytics supports both operational and research decision-making. The implementation of FAIR data principles also stood out as a critical requirement for structuring R&D data, making it more accessible, and improving interoperability. Large government-led initiatives reflected the scale and importance of these data-driven approaches. For example, the NIH All of Us Research Program had already collected data from over 400,000[iii] participants and aimed to reach more than 1 million individuals.
The implication is that data platforms and analytics capabilities are becoming embedded in enterprise decision-making, connecting research, clinical, and operational domains through more consistent use of evidence and insight.
The event also showed that pharma companies are increasingly operating within broader digital health ecosystems. The focus was less on standalone technology deployments and more on how pharmaceutical organizations connect with technology providers, healthcare stakeholders, digital platforms, and data systems across the value chain.
Collaborative innovation with external partners emerged as an important part of this shift. This aligns with Avasant Life Sciences Digital Services 2026 RadarView, which highlights the growing role of service providers and strategic partnerships in building integrated digital ecosystems by combining AI, cloud, data platforms, and analytics across the life sciences value chain to enable end-to-end innovation and collaboration. Digital technologies also emerged as enablers of patient-centered drug development, particularly through the use of patient data, digital tools, and engagement models in research and development processes.
This points to a shift toward ecosystem-based operating models, where pharmaceutical companies work as part of interconnected networks spanning technology, healthcare delivery, and patient engagement.
The governance discussions underscored that digital pharma cannot scale on technology capability alone. Participants placed regulatory, compliance, cybersecurity, and ethics considerations at the center of the conversation, particularly as AI and data-driven systems become more deeply embedded across pharmaceutical operations.
The central challenge was balancing innovation with control. Speakers discussed AI/ML compliance and implementation in tightly regulated research and clinical environments. They also emphasized data privacy, data integrity, and cybersecurity in digital R&D, given the need to manage large volumes of sensitive clinical and patient data. In addition, they highlighted the importance of governance and transparency in AI-driven processes, including oversight mechanisms to monitor model performance, ensure accountability, and support auditability.
At a broader level, pharma’s ability to scale AI will hinge on the maturity of its governance frameworks. Compliance, validation, traceability, and data standards remain critical in clinical development and research environments where regulatory confidence is essential.
The patient-centered drug development and precision medicine discussions showed how analytics and digital technologies are reshaping research design and treatment approaches. Drug development teams are increasingly using patient-level data and digital tools to better align clinical research with patient outcomes. Global spending on precision medicine treatment reached nearly $32 billion[iv] in 2022 and is projected to exceed $124 billion by 2027, underscoring the growing emphasis on personalized treatment and individualized patient interventions. Even so, the speakers agreed that clinical trials remain the gold standard for evaluating the safety and efficacy of such therapies.
The role of big data in making precision medicine more actionable emerged as a key point in the discussions. Speakers highlighted how large-scale datasets are helping researchers identify patterns across patient populations and support targeted treatment strategies. They also emphasized that patient-centric clinical and research models are incorporating patient data, real-world insights, and digital engagement tools into study design and therapeutic development.
This indicates a growing reliance on data-driven approaches to enable segmented, personalized treatment models, in which therapies are developed and evaluated based on specific patient characteristics and clinical profiles. It also brings research processes and patient-focused outcomes closer together by integrating analytics and digital capabilities.
Across the event, a clear shift emerged away from traditional, stage-based pharmaceutical operating models. Companies are applying AI, data science, and advanced digital technologies across the life cycle of drug development and delivery, spanning early research, clinical development, regulatory activities, and post-market evaluation.
Digital technologies are enabling more integrated workflows across life cycle stages, allowing data generated in discovery, clinical trials, and real-world settings to be connected and reused across multiple functions. AI and analytics are supporting the processing of large-scale biological and clinical datasets, while digital infrastructure is improving coordination between research, clinical, and operational teams.
These developments are contributing to more coordinated, data-supported processes, including improvements in development timelines, clinical trial execution, and regulatory documentation, enabled by structured data flows and analytics-driven insights. Digital health tools and patient data are also extending visibility into therapeutic outcomes beyond traditional trial environments.
The result is the emergence of connected life cycle models, where pharmaceutical activities are not managed as isolated stages but as part of an integrated system supported by shared data, digital platforms, and analytical capabilities. This shift has implications for how therapies are discovered, developed, evaluated, and monitored in real-world settings.
The Digi‑Tech Pharma & AI 2026 signals several structural shifts that industry stakeholders will need to track as digital technologies, data-driven approaches, and regulatory alignment become more deeply embedded across the drug development life cycle:
For Avasant, these structural shifts point to a broader transition in the pharmaceutical industry toward integrated, data-enabled, and digitally supported operating models across the drug development life cycle. The convergence of AI, real-world data, digital platforms, and regulatory frameworks reflects a move away from isolated, process-driven approaches toward more coordinated and technology-aligned systems. As pharmaceutical organizations incorporate these capabilities across research, clinical development, and patient engagement, the emphasis will increasingly be on aligning innovation with compliance, governance, and data standards.
Digi‑Tech Pharma & AI 2026 reflects the growing incorporation of digital technologies, data systems, and AI tools across pharmaceutical research, development, and care delivery. The event reinforced the importance of integrating these capabilities into existing industry processes while keeping regulatory compliance, data governance, and cybersecurity at the center of adoption.
The event also underscored the growing importance of collaborative innovation, digital health ecosystems, and patient-centered drug development. Pharma organizations are increasingly working alongside technology providers and healthcare stakeholders to support end-to-end processes, while real-world data and analytics are becoming more important in regulatory and clinical workflows.
Overall, Avasant views the industry as moving toward data-integrated and digitally enabled operating models, with implications for how pharmaceutical organizations structure R&D processes, engage with regulatory frameworks, and collaborate across the healthcare ecosystem. This reflects the integration of digital capabilities into core activities across the pharmaceutical life cycle, including discovery, clinical development, and patient-focused outcomes.
[i] https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/artificial-intelligence-drug-development
[ii] https://www.ema.europa.eu/en/about-us/how-we-work/data-regulation-big-data-other-sources/real-world-evidence/data-analysis-real-world-interrogation-network-darwin-eu
[iii] https://www.jabfm.org/content/37/Supplement2/S144
[iv] https://www.americanpharmaceuticalreview.com/Featured-Articles/611945-Precision-Medicine-in-Clinical-Trials-A-Statistical-Perspective/
By Parnika Gupta, Research Analyst, and Eratha Poongkuntran, Associate Director, Avasant
Avasant’s research and other publications are based on information from the best available sources and Avasant’s independent assessment and analysis at the time of publication. Avasant takes no responsibility and assumes no liability for any error/omission or the accuracy of information contained in its research publications. Avasant does not endorse any provider, product or service described in its RadarView™ publications or any other research publications that it makes available to its users, and does not advise users to select only those providers recognized in these publications. Avasant disclaims all warranties, expressed or implied, including any warranties of merchantability or fitness for a particular purpose. None of the graphics, descriptions, research, excerpts, samples or any other content provided in the report(s) or any of its research publications may be reprinted, reproduced, redistributed or used for any external commercial purpose without prior permission from Avasant, LLC. All rights are reserved by Avasant, LLC.
Login to get free content each month and build your personal library at Avasant.com
